Table 1. The various published single-institution reports of outcomes and toxicity using intensity-modulated radiotherapy for radiation delivery in oropharyngeal cancers.
| Author | Patients, n | Stage | CRT | LRC | OS | Incidence >Grade 2 xerostomia | Incidence ORN | POF |
| Huang et al [80] | 71 | III–IV | 100% | 94% (3 years) | 83% (3 years) | 33% | 1% | All HD |
| De Arruda et al [81] | 50 | I–IV | 86% | 98% (2 years) | 98% (2 years) | 33% | 0% | All HD |
| Lee et al [18] | 41 | III–IV | 100% | 92% (2 years) | 91% (2 years) | 12% | 0% | All HD |
| Chao et al [82] | 74 | I–IV | 22% | 87% (4 years) | 87% (4 years) | 12% | 0% | All HD |
| Garden et al [83] | 51 | I–IV | 9% | 93% (2 years) | 93% (2 years) | NR | 2% | All HD |
| Eisbruch et al [84] | 69 | I–III | 0% | 91% (2 years) | 96% (2 years) | 16% | 6% | All HD |
| Sanguineti et al [40] | 50 | III–IV | 0% | 94% (3 years) | NR | NR | NR | 96% in HD |
CRT, concomitant radiotherapy; HD, high-dose region; LRC, locoregional control; NR, not reported; ORN, osteoradionecrosis of the mandible; OS, overall survival; POF, pattern of failure.